Professor Gourley and his dedicated team of doctors and researchers recently hosted an event to express their gratitude for the ongoing support of their research to advance low-grade serous ovarian cancer (LGSOC). Attendees included individuals with LGSOC and their families, who have contributed to fundraising efforts through the Low-Grade Serous Ovarian Cancer Initiative.
Alex Coppock-Bunce has been supporting Professor Gourley’s research since her diagnosis in 2018, through her artwork, with sales through her Facebook page, “Alex Coppock-Bunce Artsworld” contributing to their crucial research.
Community Support for Cutting-Edge Research
The event included a presentation by Professor Gourley, highlighting the significant research strides his team is making to find new treatments for LGSOC. He expressed a deep appreciation for the fundraising efforts of those in attendance, noting how vital their contributions are to the progress being made.
Using advanced techniques like tumour sequencing, and the cultivation of LGSOC organoids and cell cultures, they have been able to generate novel data about the genes that drive this tumour and new drugs that might be effective.
Their efforts are supported by a unique database that allows them to track and observe outcomes of people with LGSOC. They are making progress through a comprehensive broad approach, incorporating various disciplines and biological profiles to identify effective treatments.
The researchers were eager to share their work and discuss their findings, creating an atmosphere of collaboration and hope.
International Collaboration
LGSOC is now recognised as a separate disease to high-grade serous ovarian cancer and there has been a significant increase in global cooperation. Professor Gourley’s team is collaborating with researchers in Australia, Canada, the US and beyond, alongside others in the UK on areas of interest including gene sequencing projects, and treatment resistance.
A Glimpse into the Labs
Attendees were given a tour of the laboratories, where they were able to observe slides of LGSOC cancer under powerful microscopes. Attendee Alex Coppock-Bunce said the sight of these cells was both surprising and emotional. Despite their beauty under the microscope, she was reminded of the devastation they cause in the lives of those affected by LGSOC. Yet, seeing the cells first hand allowed her to visualise their destruction through treatment, bringing a sense of optimism.
Moving Forward
The event also included discussions on the RAMP 301 trial, which is exploring a novel combination treatment that may enhance the effectiveness of MEK inhibitors, along with other new treatments.
The importance of continued fundraising was made clear, as every penny contributes to the development of treatments specifically tailored for LGSOC, moving away from the less effective, generalised treatments of the past.
In the evening, attendees had the opportunity to connect with one another, share their experiences, and exchange valuable information, underscoring the importance of community in providing emotional support and sharing knowledge.
A Hopeful Future
As the day concluded, the sense of hope was palpable. Seeing the research first hand made the progress feel real and personal, leaving everyone eager to return next year and witness the advancements that have been made. Every day brings us closer to a cure for LGSOC, and the collaborative efforts of researchers, patients, and fundraisers are paving the way for a brighter future.
